Novel vaccine for preventing and treating merkel cell carcinoma
AssigneeAdvaccine (Suzhou) Biopharmaceuticals Co. Ltd.
InventorsYue HE, Gan ZHAO, Lunan ZHANG, Xin CHENG, Qingling YU
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel vaccine for preventing and treating Merkel cell carcinoma. The present invention constructs a therapeutic vaccine based on a Merkel cell polyomavirus capsid protein VP1 by taking the Merkel cell polyomavirus capsid protein VP1 as an antigen, in combination with a TLR agonist. The present invention effectively solves the problem of prevention and treatment of the Merkel cell carcinoma and has great application value and application prospects.
Claims15
A vaccine composition against Merkel cell carcinoma, wherein the vaccine composition comprises:
- Merkel cell polyomavirus capsid protein VP1 or a plasmid comprising a gene encoding the Merkel cell polyomavirus capsid protein VP1;
- and a TLR agonist selected from one or more of CpG, R848, and MPL.
An encoding gene of Merkel cell polyomavirus capsid protein VP1, wherein the encoding gene comprises a nucleotide sequence having 71.9%-74.7% homology to SEQ ID No. 6.
Dependencies are inferred from the claim text.